Fisher Wallace Laboratories, Inc.

Fisher Wallace Laboratories, Inc. is a manufacturing startup with the slogan "Better tech for mental health." The company has been in operation since 2007 and is based in the United States. Fisher Wallace Labs aims to enhance access to mental healthcare by developing and bringing to market wearable brain stimulation technology for the treatment of depression, anxiety, and other neuropsychiatric and cognitive disorders. The company's technology has shown promising results in clinical trials for the treatment of Major Depressive Disorder and Generalized Anxiety Disorder, with successful collaborations with institutions like the Seattle Police Department and Washington State University. Fisher Wallace Labs previously obtained temporary FDA clearance and achieved considerable success, distributing 100,000 Version 1.0 devices through 14,000 prescribers, generating $40 million in revenue. The company also secured Medicaid reimbursement in Maine (MaineCare). Notably, the latest $2.50M Venture Round investment on 29 March 2022 came from SHUFL Capital. Currently, Fisher Wallace Labs is focused on obtaining regulatory approval for OAK, its Version 2.0 technology, aiming for commercialization in 2025 and eventually achieving smartphone scale.